Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WVE-120101 in Huntington's Disease
NCT03225833Phase 2Terminated
- Sponsor
- Wave Life Sciences
- Start
- Jul 2017
- Primary completion
- May 2021
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 7
01
Overview
A Phase 2 trial of rovanersen in Huntington's disease (HD), sponsored by Wave Life Sciences. Started Jul 2017; status: terminated.
02
Drugs
rovanersen
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT03225833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03225833.